FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1510442926> ?p ?o ?g. }

• W1510442926 endingPage "12" @default.
• W1510442926 startingPage "1" @default.
• W1510442926 abstract "Recent progress in cancer immunotherapy has been remarkable. Most striking are the clinical development and approval of immunomodulators, also known as immune checkpoint inhibitors. These monoclonal antibodies (mAb) are directed to immune checkpoint molecules, which are expressed on immune cells and mediate signals to attenuate excessive immune reactions. Although mAbs targeting tumor associated antigens, such as anti-CD20 mAb and anti-Her2 mAb, directly recognize tumor cells and induce cell death, immune checkpoint inhibitors restore and augment the antitumor immune activities of cytotoxic T cells by blocking immune checkpoint molecules on T cells or their ligands on antigen presenting and tumor cells. Based on preclinical data, many clinical trials have demonstrated the acceptable safety profiles and efficacies of immune checkpoint inhibitors in a variety of cancers. The first in class approved immune checkpoint inhibitor is ipilimumab, an anti-CTLA-4 (cytotoxic T lymphocyte antigen-4) mAb. Two pivotal phase III randomized controlled trials demonstrated a survival benefit in patients with metastatic melanoma. In 2011, the US Food and Drug Administration (FDA) approved ipilimumab for metastatic melanoma. Several clinical trials have since investigated new agents, alone and in combination, for various cancers. In this review, we discuss the current development status of and future challenges in utilizing immune checkpoint inhibitors." @default.
• W1510442926 created "2016-06-24" @default.
• W1510442926 creator A5015229603 @default.
• W1510442926 creator A5063536443 @default.
• W1510442926 creator A5080299485 @default.
• W1510442926 creator A5090471753 @default.
• W1510442926 date "2015-01-01" @default.
• W1510442926 modified "2023-10-15" @default.
• W1510442926 title "Clinical Development of Immune Checkpoint Inhibitors" @default.
• W1510442926 cites W1965494873 @default.
• W1510442926 cites W1971554504 @default.
• W1510442926 cites W1977144608 @default.
• W1510442926 cites W1984545852 @default.
• W1510442926 cites W2004630197 @default.
• W1510442926 cites W2010121426 @default.
• W1510442926 cites W2013043293 @default.
• W1510442926 cites W2016732129 @default.
• W1510442926 cites W2021588881 @default.
• W1510442926 cites W2025909187 @default.
• W1510442926 cites W2028376975 @default.
• W1510442926 cites W2029208213 @default.
• W1510442926 cites W2038914273 @default.
• W1510442926 cites W2040851929 @default.
• W1510442926 cites W2041672829 @default.
• W1510442926 cites W2042576421 @default.
• W1510442926 cites W2049163935 @default.
• W1510442926 cites W2050477250 @default.
• W1510442926 cites W2052730188 @default.
• W1510442926 cites W2053366731 @default.
• W1510442926 cites W2053967595 @default.
• W1510442926 cites W2055175265 @default.
• W1510442926 cites W2059928795 @default.
• W1510442926 cites W2061071534 @default.
• W1510442926 cites W2066671159 @default.
• W1510442926 cites W2075819066 @default.
• W1510442926 cites W2080886891 @default.
• W1510442926 cites W2082625828 @default.
• W1510442926 cites W2087186136 @default.
• W1510442926 cites W2094366129 @default.
• W1510442926 cites W2095826876 @default.
• W1510442926 cites W2097855813 @default.
• W1510442926 cites W2097995306 @default.
• W1510442926 cites W2100696012 @default.
• W1510442926 cites W2101653483 @default.
• W1510442926 cites W2103220202 @default.
• W1510442926 cites W2104885590 @default.
• W1510442926 cites W2104925898 @default.
• W1510442926 cites W2105396178 @default.
• W1510442926 cites W2107484016 @default.
• W1510442926 cites W2107863654 @default.
• W1510442926 cites W2108933323 @default.
• W1510442926 cites W2117973220 @default.
• W1510442926 cites W2118982164 @default.
• W1510442926 cites W2119198740 @default.
• W1510442926 cites W2119895292 @default.
• W1510442926 cites W2121080857 @default.
• W1510442926 cites W2121770645 @default.
• W1510442926 cites W2122495232 @default.
• W1510442926 cites W2123363005 @default.
• W1510442926 cites W2127737941 @default.
• W1510442926 cites W2128035403 @default.
• W1510442926 cites W2130066229 @default.
• W1510442926 cites W2130473166 @default.
• W1510442926 cites W2130826590 @default.
• W1510442926 cites W2133075384 @default.
• W1510442926 cites W2133131866 @default.
• W1510442926 cites W2133294507 @default.
• W1510442926 cites W2134638467 @default.
• W1510442926 cites W2135707184 @default.
• W1510442926 cites W2136746908 @default.
• W1510442926 cites W2137187071 @default.
• W1510442926 cites W2138134458 @default.
• W1510442926 cites W2140419562 @default.
• W1510442926 cites W2141579931 @default.
• W1510442926 cites W2143163879 @default.
• W1510442926 cites W2147621820 @default.
• W1510442926 cites W2149244682 @default.
• W1510442926 cites W2154391127 @default.
• W1510442926 cites W2155189639 @default.
• W1510442926 cites W2155995527 @default.
• W1510442926 cites W2156253417 @default.
• W1510442926 cites W2160834915 @default.
• W1510442926 cites W2163184777 @default.
• W1510442926 cites W2164433065 @default.
• W1510442926 cites W2164918836 @default.
• W1510442926 cites W2171190137 @default.
• W1510442926 cites W2560367415 @default.
• W1510442926 cites W2572174216 @default.
• W1510442926 doi "https://doi.org/10.1155/2015/605478" @default.
• W1510442926 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4486755" @default.
• W1510442926 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26161407" @default.
• W1510442926 hasPublicationYear "2015" @default.
• W1510442926 type Work @default.
• W1510442926 sameAs 1510442926 @default.
• W1510442926 citedByCount "50" @default.
• W1510442926 countsByYear W15104429262015 @default.
• W1510442926 countsByYear W15104429262016 @default.
• W1510442926 countsByYear W15104429262017 @default.

• next